[Skip to Content]
[Skip to Content Landing]
September 10, 1997

Study of Bisphosphonates Leads to New Views of Bone Remodeling, Therapy for Skeletal Malignancy

JAMA. 1997;278(10):803-804. doi:10.1001/jama.1997.03550100025010

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


CHEMICAL compounds called bisphosphonates, some of which were originally used as water softeners, are playing an increasing role in the treatment of metastatic skeletal malignancies. The development may provide new insights into the normal processes involved in bone remodeling.

Some solid tumors, especially those of the breast, prostate, and lung, readily metastasize to bone, where they stimulate its formation or, more frequently, its destruction. Since bisphosphonates inhibit bone turnover by decreasing bone resorption, investigators have become interested in studying their possible use for controlling or even preventing metastatic skeletal lesions.

"We've been remiss in not considering this specific problem of bone metastasis. We need to understand it to develop rational ways of preventing and treating it. The information is now available or is on the horizon which can really make a difference in this process," said Gregory Mundy, MD, introducing a symposium last month at the National Institutes of Health